Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of QR052107B in refractory or unexplained chronic cough
CTR20222727Phase 2Active
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd.
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of relicpixant in refractory chronic cough (RCC), chronic idiopathic cough (CIC), sponsored by Wuhan Createrna Science and Technology Co., Ltd.. Started Nov 2023; status: active.
02
Drugs
relicpixant
03
Conditions
refractory chronic cough (RCC)chronic idiopathic cough (CIC)
Beyond the preview
Go deeper on CTR20222727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222727.